
Lilly
1876
150
2026
YEARS OF MEDICINE


Eli Lilly and Company
Q2 2026
Earnings Call
Lilly

Agenda

Introduction and Key Events
David Ricks, Chair and Chief Executive Officer

Q2 2026 Financial Results
Lucas Montarce, Chief Financial Officer

R&D Update
Dan Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer

Question & Answer Session

Safe Harbor Provision and Other Information

This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation and investigations; business development transactions; trade and economic conditions; the implementation of our voluntary agreement with the U.S. government related to drug pricing and access; and changes in laws and regulations, including healthcare reform.

For additional information about the factors that affect the company's business, please see the company's latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. Certain financial information in this presentation is presented on a non-GAAP basis. Investors should refer to the reconciliations included in this presentation and should consider the company's non-GAAP measures in addition to, not as a substitute for or superior to, measures prepared in accordance with GAAP. These materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval or become commercially available for the uses being investigated. Numbers in this presentation may not add due to rounding. Market positions represent estimates for performance based on indicated data sources. These figures do not reflect Lilly's share of any relevant antitrust market and do not include the full set of therapeutic or other alternatives reasonably available to patients and prescribers.

The company undertakes no duty to update forward-looking statements except as required by applicable law.

Q2 2026 Progress on Strategic Deliverables

Broaden Impact on Cardiometabolic Health

- Incretin revenue grew 67% driven by market growth and increased global share
- Expanded access to obesity medicines through Medicare GLP-1 Bridge program
- Positive data in TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 for retatrutide
- Positive CHMP opinion for Onswik (insulin efsitora alfa)

Expand Presence in Other Therapeutic Areas

- 121% Key Product revenue growth in Oncology, Immunology and Neuroscience
- Ebglyss approved for once every eight weeks maintenance dosing
- Jaypirca approved in line-agnostic CLL in EU

Invest to Drive Future Growth

- Opened Lebanon Advanced Therapies genetic medicine manufacturing facility
- Produced first commercial material at Limerick manufacturing facility
- Announced acquisition of AtaiBeckley
- Completed acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company

$23.0B ↑ 48%
Q2 WORLDWIDE REVENUE

+76%
KEY PRODUCT REVENUE GROWTH

$8.38 ↑ 33%
NON-GAAP EPS

Growth rates reflect change vs Q2 2025
The Company currently defines Key Products as Ebglyss, Foundayo (added Q2 2026), Inluriyo, Jaypirca, Kisunla, Mounjaro, Omvoh, and Zepbound
Incretins include Foundayo, Mounjaro, Zepbound and Trulicity

Medicare GLP-1 Bridge Progress

~20 million	Potential patients eligible under the Medicare Bridge Program
$50 / month	Out of pocket cost for Medicare beneficiaries
~60 - 70%	Patients are new incretin starts
~35%	Increase in U.S. covered lives for Lilly obesity medicines

Q2 2026 Key Income Statement Measures (unaudited)

Dollars in millions; except per share data

	GAAP Reported	Adjustments	Non-GAAP Adjusted	YoY Non-GAAP Adjusted Change
Total revenue	$22,974	$ -	$22,974	48%
Gross margin	85.8%	0.5pp	86.3%	+1.3pp
Total operating expense	$10,728	$(703)	$10,025	61%
Operating income	$8,978	$828	$9,806	40%
Other income (expense)	$269	$(445)	$(176)	-7%
Effective tax rate	23.3%	-1.1pp	22.2%	+5.7pp
Net income	$7,095	$398	$7,493	32%
EPS	$7.94	$0.44	$8.38	33%
Acquired IPR&D Charge per share[1]	$3.03	$ -	$3.03	NM

[1] Acquired IPR&D (in-process research and development) charge of $2.8 billion (pre-tax).

Performance Margin[2]	51.2%		54.8%	+8.9pp

[2] The Company defines Performance Margin as gross margin less research and development, marketing, selling and administrative, and asset impairment, restructuring and other special charges divided by revenue

Note: The Non-GAAP Performance Margin excludes the amortization of intangible assets. The applicable impact of amortization of intangible assets can be found in the reconciliation tables on slide 23.

Price/Rate/Volume Effect on Revenue

Dollars in millions

Q2 2026

	Amount	Price	FX Rate	Volume	Total	CER
U.S.	$14,413	(3)%	-	37%	33%	33%
Europe	$4,115	7%	4%	49%	60%	55%
Japan	$628	(9)%	(9)%	39%	21%	30%
China[1]	$941	NM	9%	NM	102%	93%
Rest of world	$2,877	(4)%	7%	141%	143%	136%
Total Revenue	$22,974	(13)%	1%	60%	48%	46%

YTD 2026

	Amount	Price	FX Rate	Volume	Total	CER
U.S.	$26,532	(5)%	-	42%	37%	37%
Europe	$7,760	6%	10%	41%	56%	46%
Japan	$1,199	(4)%	(5)%	40%	30%	35%
China[1]	$1,635	NM	5%	NM	78%	73%
Rest of world	$5,648	(4)%	8%	155%	159%	151%
Total Revenue	$42,773	(13)%	2%	62%	51%	49%

Dollars in millions. Numbers may not add due to rounding. CER= price change + volume change; NM = not meaningful

[1] China price and volume driven by inclusion of Mounjaro on National Reimbursement Drug List for Type 2 Diabetes, with lower price and higher volume vs. Q2 2025 and YTD 2025

Q2 2026 Update on Key Products

$15.7B Key Product revenue, accelerating to 76% growth year over year



The Company currently defines Key Products as Ebglyss, Foundayo (added Q2 2026), Inluriyo (added Q4 2025), Jaypirca, Kisunla, Mounjaro, Omvoh, and Zepbound.

Cardiometabolic Health

Mounjaro Q2 2026 sales of $9.9B, +91% vs Q2 2025

Zepbound Q2 2026 sales of $4.9B, +46% vs. Q2 2025

Foundayo Q2 2026 sales of $98M

Immunology

Ebglyss Q2 2026 sales of $201M, +131% vs. Q2 2025

Oncology

Jaypirca Q2 2026 sales of $192M, +56% vs. Q2 2025

Inluriyo Q2 2026 sales of $75M

Neuroscience

Kisunla Q2 2026 sales of $167M

+121%

Key Product revenue growth in Immunology, Oncology & Neuroscience

U.S. Incretin Analogs Market



+31%

Q2 2026 U.S. market growth

60.9%

Lilly share of market

Source: IQVIA weekly NPA total prescriptions, weekly data 6/26/2026
Rolling 4 week SOM. Incretin analogs market includes injectable GLP-1s, oral GLP-1s and GLP-1/GIP dual agonists

International Incretin Analogs Market



+74%

Q2 2026 market growth

54.9%

Lilly share of market

Growth rate: April /May 2026 vs. April/May 2025
Data source: IQVIA GMI Agent AI, MIDAS Monthly accessed 7/29/2026
Sales in US dollars at the exchange rate in effect at the time of sale based on wholesaler purchase price and manufacturer's selling price
Market basket: Bydureon/Byetta, Foundayo, Lyxumia, Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Wegovy, Victoza, Zepbound
Geography: Worldwide excluding USA and Puerto Rico

Foundayo Launch and Clinical Progress

	US	International	Expected Phase 3 Readouts
2026	✓ Sampling and HCP engagement ✓ DTC expansion launched in June ✓ Medicare GLP-1 Bridge effective July ○ Type 2 Diabetes Regulatory Action	✓ UAE (obesity) ✓ Mexico (obesity & T2D) ✓ Saudi Arabia (obesity) ○ Select additional markets	✓ Type 2 Diabetes (ACHIEVE-4) ○ Obstructive sleep apnea
2027+	○ Continued uptake and market expansion	○ Launched in all major markets	○ Stress urinary incontinence ○ Knee osteoarthritis pain ○ Hypertension ○ Peripheral artery disease ○ Cardiovascular outcomes

Significant global multi-indication cardiometabolic opportunity building into 2027 and beyond

Mexico and Saudi Arabia approvals only; product launch later this year

YTD 2026 Capital Allocation

$ in billions



[1] Includes development milestones, closed acquisitions and cash outflows associated with equity investments
[2] After tax

2026 Guidance (Non-GAAP)

	Prior	Updated	Comments
Revenue[1]	$82.0 – $85.0 billion	$85.0 – $87.0 billion	Strong underlying business performance; increased midpoint of the range by $2.5B reflecting 32% year over year growth
Performance Margin[2]	47.0% – 48.5%	49.0% – 50.5%	Increased by 2.0pp to reflect updated revenue expectations
Tax Rate	Approximately 18-19%	Unchanged	
Earnings Per Share[3]	$35.50 – $37.00	$35.50 – $36.50	Increased $2.78 at midpoint to reflect updated revenue expectations before updating guidance for $3.03 impact of Q2 2026 acquired IPR&D charges

[1] GAAP measure
[2] The Company defines Non-GAAP Performance Margin as gross margin less research and development and marketing, selling, and administrative expenses divided by revenue.
[3] 2026 assumes shares outstanding of approximately 894 million
Note: See slide 23 for additional Non-GAAP information.
FX assumptions of 1.14 (Euro), 153 (Yen) and 7.1 (Yuan)

Retatrutide Showed Powerful Efficacy in TRIUMPH Trials

Change from Baseline Weight[1]

	TRIUMPH-1	TRIUMPH-2	TRIUMPH-3	TRIUMPH-4
	vs. placebo Obesity 80 weeks	vs. placebo Obesity with T2D 80 weeks	vs. placebo Class II-III Obesity with CVD ± T2D 80 weeks	vs. placebo Obesity with OA 68 weeks
Baseline Body Weight:	112.7 kg	106.4 kg	111.4 kg	112.7 kg



First-of-its-kind medicine delivered clinically meaningful weight loss, with most common adverse events generally consistent with other incretins

T2D = type 2 diabetes; CVD = cardiovascular disease; OA = osteoarthritis of the knee; PBO = placebo

[1] Efficacy estimand

Jaypirca PFS in R/R CLL Using a Time-Limited Regimen

BRUIN CLL-322 Select Hazard Ratios (95% CI)[1]



Disease Progression on One Prior cBTKi[1]

68% **reduction in risk of progression or death** vs VR



The overall safety profile of fixed-duration Jaypirca + VR was generally similar to VR alone

PFS = progression free survival; R/R = relapsed / refractory; CLL = chronic lymphocytic leukemia; cBTKi = covalent Bruton tyrosine kinase inhibitor; VR = venetoclax + rituximab; PD = Progressive Disease

[1] IRC-assessed progression free survival data

Significant R&D Progress through M&A

CMH	ONCOLOGY	NEUROSCIENCE	IMMUNOLOGY	INFECTIOUS DISEASE
ventyx BIOSCIENCES	kelonia Ajax THERAPEUTICS	CENTESSA PHARMACEUTICALS AtaiBeckley	ORNA®	curevo VACCINE LimmaTech Biologics VACCINE COMPANY

Note: AtaiBeckley transaction expected to close in Q3 2026

Lilly Select Pipeline

As of August 3, 2026

NME

NILEX / Other

REMOVAL

ADDITION OR MILESTONE ACHIEVED

UPDATES SINCE April 28, 2026

PHASE 2		
BRENIPATIDE *IBS-C*	BRENIPATIDE *IBS-D*	
TIRZEPATIDE *Higher Doses*	ZOTEMTEGRAST + MIRIKIZUMAB *UC*	ZOTEMTEGRAST *Crohn's Disease*
BRENIPATIDE *Schizophrenia*	BRENIPATIDE *Tobacco Use Disorder*	ELTREKIBART *Ulcerative Colitis*
BRENIPATIDE *Asthma*	BRENIPATIDE *Bipolar Disorder*	BRENIPATIDE *Opioid Use Disorder*
CLEMINOREXTON *Central Hypersomnias*	FXR AGONIST + MIRIKIZUMAB *CD*	XCL1/2 Ab *Vitiligo*
ZOTEMTEGRAST *Ulcerative Colitis*	AMEZOSVATEIN *Shingles*	CLAZAKIZUMAB *Inflammatory Disorders*
SIMEPDEKINRA *Psoriasis*	SOLBINSIRAN *Severe Hypertriglyceridemia*	TURIGROBART *Pain*
NLRP3 INH II (VTX2735) *Recurrent Pericarditis*	OTOF GENE THERAPY *Hearing Loss*	SILMORETGENE PARVEC (AIPL1-GT) *AIPL1-IRD*
NAV1.8 INH (SM) *Pain*	NISOTIROSTIDE *Diabetes*	NLRP3 INH (VTX3232) *Inflammatory Disorders*
MACUPATIDE *Obesity*	MEVIDALEN *Symptomatic AD*	NAPERIGLIPRON *Obesity*
GBA1 GENE THERAPY *Parkinson's Disease*	GIPR AGONIST LA *CINV*	GS INSULIN RECEPTOR AGONIST *Diabetes*
AT2R ANTAGONIST *Pain*	BIMAGRUMAB *Obesity*	ELTREKIBART *Hidradenitis Suppurativa*

GBA1 GENE THERAPY *Gaucher Disease Type 1*

PHASE 3			
TIRZEPATIDE *Type 1 Diabetes*			
SELPERCATINIB *Adjuvant RET+ NSCLC*	SOFETABART MIPITECAN *PSOC*	TIRZEPATIDE *Morbidity and Mortality in Obesity*	TIRZEPATIDE *MASLD*
RETATRUTIDE *Chronic Low Back Pain*	RETATRUTIDE *CV / Renal Outcomes*	RETATRUTIDE *Diabetes*	RETATRUTIDE *MASLD*
ORFORGLIPRON *Osteoarthritis Pain*	ORFORGLIPRON *Peripheral Artery Disease*	ORFORGLIPRON *Stress Urinary Incontinence*	PIRTOBRUTINIB *R/R MCL Monotherapy*
OLOMORASIB *Adj KRAS G12C+ NSCLC (unresected)*	ORFORGLIPRON *Cardiovascular Outcomes*	ORFORGLIPRON *Hypertension*	ORFORGLIPRON *Obstructive Sleep Apnea*
MIRIKIZUMAB + TIRZEPATIDE *CD*	MIRIKIZUMAB + TIRZEPATIDE *UC*	OLOMORASIB *1L KRAS G12C+ NSCLC (PD-L1 high)*	OLOMORASIB *Adj KRAS G12C+ NSCLC (resected)*
IXEKIZUMAB + TIRZEPATIDE *PsA*	IXEKIZUMAB + TIRZEPATIDE *Psoriasis*	LEBRIKIZUMAB *AR (perennial allergens)*	LEBRIKIZUMAB *CRSwNP*
ELORALINTIDE INCRETIN ADD-ON *Obesity*	ELORALINTIDE *Obstructive Sleep Apnea*	ELORALINTIDE *Osteoarthritis Pain*	IMLUNESTRANT *Adjuvant Breast Cancer*
SOFETABART MIPITECAN *PROC*	BARICITINIB *Type 1 Diabetes*	BRENIPATIDE *Major Depressive Disorder*	DONANEMAB *Cognitively Unimpaired AD*
MUVALAPLIN *ASCVD*	OLOMORASIB *1L KRAS G12C+ NSCLC (All PD-L1)*	REMTERNETUG *Cognitively Unimpaired / MCI due to AD*	RETATRUTIDE *Obesity, OA, OSA*
BRENIPATIDE *Alcohol Use Disorder*	ELORALINTIDE *Obesity*	IXO-VEC *wet Age-Related Macular Degeneration*	LEPODISIRAN *ASCVD*

APPROVED
PIRTOBRUTINIB *1L CLL Monotherapy*

REG REVIEW
PIRTOBRUTINIB *R/R CLL Combination*
TIRZEPATIDE *Cardiovascular Outcomes*
ORFORGLIPRON *Diabetes*
INSULIN EFSITORA ALFA *Diabetes*

Potential Key Events 2026

New since last update

Phase 3 Initiations

- Eloralintide for obesity or overweight
- Eloralintide incretin add-on for obesity or overweight
- Eloralintide for OA knee pain and obesity or overweight
- Eloralintide for OSA and obesity or overweight
- Orforglipron for peripheral artery disease
- Vepugratinib for 1L metastatic urothelial cancer
- Tersolisib for advanced breast cancer
- Sofetabart Mipitecan for platinum-resistant ovarian cancer
- Sofetabart Mipitecan for platinum-sensitive ovarian cancer
- Brenipatide for major depressive disorder
- Baricitinib for type 1 diabetes

Phase 3 Data Disclosures

- Ixekizumab and tirzepatide for psoriatic arthritis and obesity or overweight
- Ixekizumab and tirzepatide for psoriasis and obesity or overweight
- Orforglipron for type 2 diabetes [ACHIEVE-4]
- Orforglipron for obstructive sleep apnea
- Retatrutide for obesity or overweight [TRIUMPH 1✓/2✓/3✓]
- Retatrutide for type 2 diabetes [TRANSCEND-T2D 1✓/2/3]
- Lebrikizumab for pediatric atopic dermatitis
- Pirtobrutinib for R/R CLL combination [BRUIN CLL-322]

Regulatory Submissions

- Orforglipron for type 2 diabetes [US✓/ EU✓/J✓]
- Orforglipron for obstructive sleep apnea and obesity or overweight
- Retatrutide for overweight or obesity (now expected 2027)
- Retatrutide for OSA and obesity or overweight (now expected 2027)
- Retatrutide for OA pain of the knee and obesity or overweight (now expected 2027)
- Pirtobrutinib for R/R CLL combination
- Selpercatinib for adjuvant RET fusion-positive non-small cell lung cancer
- Lebrikizumab for pediatric atopic dermatitis

Regulatory Actions

- Zepbound KwikPen [US]
- Tirzepatide for cardiovascular outcomes
- Orforglipron for overweight or obesity [US]
- Orforglipron for type 2 diabetes
- Insulin efsitora alfa for type 2 diabetes
- Pirtobrutinib for 1L CLL [EU]
- Lebrikizumab maintenance dosing once every 8 weeks

Q2 2026 Summary

↑ 48%
Revenue growth

$8.38
Non-GAAP EPS

2 Label Expansions

Ebglyss™ (lebrikizumab-lbkz)

Jaypirca® pirtobrutinib

2 Manufacturing site milestones

3 Positive Phase 3 Retatrutide Trials

4 Acquisitions announced

VACCINE COMPANY

LimmaTech Biologics

curevo VACCINE

AtaiBeckley

Increased full year revenue guidance

$85.0B - $87.0B

Increased non-GAAP EPS guidance

$35.50 - $36.50

Broaden Impact on Cardiometabolic Health

Expand Presence in Other Therapeutic Areas

Invest to Drive Future Growth

Supplemental Slides

2026 Income Statement – Reported

Dollars in millions; except per share data

	Q2 2026	Change
Total revenue	**$22,974**	48%
Gross margin	**85.8%**	+1.5pp
Total operating expense*	**$10,728**	72%
Operating income	**$8,978**	31%
Operating margin	**39.1%**	-5.0pp
Other income (expense)	**$269**	NM
Effective tax rate	**23.3%**	+6.8pp
Net income	**$7,095**	25%
EPS	**$7.94**	26%

* Includes research and development expense; marketing, selling and administrative; acquired in-process research and development charges; and asset impairment, restructuring and other special charges (as applicable)

EPS Reconciliation

	Q2 2026	Q2 2025	% Change
Earnings per share (reported)	$7.94	$6.29	26%
Asset impairment, restructuring and other special charges	0.72	--	NM
Amortization of intangible assets	0.11	0.11	(1)%
Net losses (gains) on investments in equity securities	(0.39)	(0.09)	NM
Earnings per share (Non-GAAP)	$8.38	$6.31	33%
Acquired IPR&D	$3.03	$0.14	NM

Numbers may not add due to rounding; see slide 24 for more details on these adjustments; NM = not meaningful

Q2 Non-GAAP Adjustments

Q2 2026 non-GAAP information has been adjusted to exclude:

- Asset impairment, restructuring and other special charges, driven primarily by Kelonia and Centessa acquisition and integration costs, totaling $703 million (pre-tax), or $0.72 per share (after-tax)
- Amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $125 million (pre-tax), or $0.11 per share (after-tax)
- Net gains on investments in equity securities totaling $445 million (pre-tax), or ($0.39) per share (after-tax)

Q2 2025 non-GAAP information has been adjusted to exclude:

- Amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $122 million (pre-tax), or $0.11 per share (after-tax)
- Net gains on investments in equity securities totaling $99 million (pre-tax), or ($0.09) per share (after-tax)

Q2 2026 Mounjaro Sales Increased $4.7B

U.S. sales were $4.8 billion
International sales were $5.2 billion



U.S. TRX SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data June 26, 2026; RA = rolling average
TRx data is representative of the Incretin Analogs - type 2 diabetes market

Q2 2026 Zepbound Sales Increased $1.5B

U.S. sales were $4.9 billion[1]



[1] Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the United States. International sales were $55 million in Q2 2026

U.S. TRX SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data June 26, 2026; RA = rolling average
TRx data is representative of the branded incretin analogs – OMM market

Select Trials – Abemaciclib

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03155997[1]	Breast Cancer	Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)	3	5637	Invasive Disease-Free Survival	Mar 2020	May 2029
NCT05169567	Breast Cancer	Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMONARCH)	3	368	Progression-Free Survival (PFS)	Feb 2024	Dec 2027

[1] Also lists NSABP Foundation Inc

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Baricitinib

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT07222332	Type 1 Diabetes	A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)	3	300	Change from Baseline in C-peptide Area Under the Curve (AUC)	Jul 2028	Jul 2028
NCT07222137	Type 1 Diabetes	A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (BARICADE-DELAY)	3	150	Time from Baseline to Diagnosis of Stage 3 Type 1 Diabetes	Jul 2031	Jul 2031

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Brenipatide

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT07412756	Major Depressive Disorder	A Study of Brenipatide in Adult Participants With Major Depressive Disorder (RENEW-MDD-1)	3	1000	Time to Relapse as Measured by Number of Days from Randomization to Date Participant Meets Any Relapse Criterion of MDD	Feb 2028	Feb 2028
NCT07219966	Alcohol Use Disorder	A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)	3	1100	Change in Drinking Patterns in Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method (TLFB)	Apr 2028	Apr 2028
NCT07219953	Alcohol Use Disorder	A Study of Brenipatide in Participants With Alcohol Use Disorder (RENEW-ALC-2)	3	1100	Change in Drinking Patterns in Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method (TLFB)	Apr 2028	Apr 2028
NCT07420283	Opioid Use Disorder	A Study of Brenipatide in Participants With Opioid Use Disorder (RENEW-Op-1)	2	465	Percentage of weeks abstinence from opioid use defined by both negative urine drug screen (UDS) and no self-report of opioid use based on timeline follow back (TLFB) Achievement of >=80% weeks of abstinence from opioid use defined by both negative UDS and no self-report of opioid use based on TLFB	Mar 2028	Mar 2028
NCT07286175	Bipolar Disorder	A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)	2	400	Time to Relapse Defined as Days from Randomization to the Date on Which the Participant Meets Any Relapse Criterion	Nov 2027	Nov 2027
NCT07223840	Tobacco Use Disorder	A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse (RENEW-Smk-1)	2	222	Percentage of Participants that Achieve Carbon Monoxide (CO)-Confirmed Continuous Abstinence from Cigarette Smoking with Allowed Slips	Feb 2027	Feb 2027
NCT07410507	Schizophrenia	A Study of Brenipatide in Adult Participants With Schizophrenia (RENEW-Scz-1)	2	450	Percent Change from Baseline in Body Weight in Participants with a Baseline Body Mass Index ≥25.0 Kilograms per Meter Squared (kg/m²)	Nov 2027	Nov 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Brenipatide (cont.)

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT07219173	Asthma	A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma (RENEW-Asthma)	2	531	Annualized Asthma Exacerbation Rate Over 52 Weeks of Treatment	Apr 2028	Jun 2028
NCT07545759	Irritable Bowel Syndrome / Diarrhea	A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) (RENEW-IBS-D)	2	531	Percentage of Participants Who Had a Daily Composite Response for at Least 50 Percent (%) of Days	Sep 2027	Nov 2027
NCT07545772	Irritable Bowel Syndrome / Constipation	A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) (RENEW-IBS-C)	2	342	Percentage of Participants with a Weekly Composite Clinical Response for at Least 50 Percent (%) of Weeks	Jul 2027	Sep 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Donanemab

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04437511	Alzheimer's Disease	A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)	3	1736	Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population)	Apr 2023	Nov 2028
NCT05026866	Alzheimer's Disease	A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)	3	2996	Time to Clinical Progression of Composite Endpoint as Measured by Clinical Dementia Rating (CDR)	Nov 2027	Nov 2027
NCT05508789	Alzheimer's Disease	A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)	3	1500	Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS)	May 2028	Jul 2028
NCT05738486	Alzheimer's Disease	A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)	3	1175	Percentage of Participants with Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E)	May 2024	May 2027
NCT07571161	Alzheimer's Disease	Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease	3	140	Time to Clinical Progression as Measured by Clinical Dementia Rating-Global Score (CDR-GS)	Apr 2030	Apr 2030
NCT07602582	Alzheimer Disease / Dementia / Plaque, Amyloid	A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).	3	550	Change from Baseline as Measured by Clinical Dementia Rating - Sum of Boxes (CDR-SB)	Sep 2029	Sep 2029
NCT07589595	Cognitive Dysfunction / Lewy Body Disease / Synucleinopathies / Amyloid	A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology (TRAILBLAZER-ALZ 7)	2	350	Change from Baseline on Clinical Dementia Rating - Sum of Boxes (CDR-SB)	Aug 2028	Aug 2028

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Eloralintide

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT07321886	Obesity / Overweight	A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes (ENLIGHTEN-1)	3	1980	Percent Change from Baseline in Body Weight	Mar 2028	Jul 2030
NCT07282600	Obesity / Overweight	A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes (ENLIGHTEN-2)	3	1035	Percent Change from Baseline in Body Weight	Jan 2028	Feb 2028
NCT07369011	Obstructive Sleep Apnea / Obesity	A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ENLIGHTEN-3)	3	800	Percent Change from Baseline in Body Weight and Change from Baseline in Apnea-Hypopnea Index	Mar 2028	Apr 2028
NCT07353931	Osteoarthritis / Overweight	Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight (ENLIGHTEN-4)	3	900	Percent Change from Baseline in Body Weight and Change from Baseline in WOMAC Pain Subscale Score	Mar 2028	May 2028
NCT07392190	Obesity / Overweight	A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin (ENLIGHTEN-6)	3	900	Percent Change from Baseline in Body Weight	Jun 2028	Jul 2028
NCT06603571	Obesity	A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes	2	367	Percent Change from Baseline in Body Weight	July 2026	Aug 2026

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Imlunestrant

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04975308	Breast Neoplasms	A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3)	3	874	Progression-Free Survival (PFS)	Jun 2024	Aug 2027
NCT05514054	Breast Neoplasms	A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)	3	8000	Invasive Disease-Free Survival (iDFS)	Oct 2027	Mar 2032
NCT07287098	Breast Neoplasms	A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (preEMBER)	2	600	Percent Change from Baseline in Ki67	Jan 2029	Dec 2029

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Ixekizumab

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06588283	Plaque Psoriasis / Obesity	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight (TOGETHER-PsO)	3	281	Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and at Least 10% Weight Reduction	Jan 2026	June 2026
NCT06588296	Psoriatic Arthritis / Obesity	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (TOGETHER-PsA)	3	279	Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction	Nov 2025	Apr 2026

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Lebrikizumab

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05559359	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)	3	377	Percentage of Participants With Investigator Global Assessment (IGA) Score of 0 or 1 at Week 16 and a Reduction ≥2 points from Baseline	Jan 2026	Dec 2026
NCT05735483	Atopic Dermatitis	A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)	3	333	Percentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs)	Dec 2027	Apr 2029
NCT06339008	Perennial Allergic Rhinitis	A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)	3	450	Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at week 16	Sep 2026	Oct 2028
NCT06338995	Chronic Rhinosinusitis With Nasal Polyps	A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)	3	510	Mean Change From Baseline (CFBL) in Participant Reported Nasal Congestion Score (NCS) Severity	May 2027	Mar 2028
NCT06280716	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis (Advance-Asia)	3	301	Percentage of Participants Achieving Eczema Area and Severity Index (EASI-75) ≥75% Reduction in EASI Score for Mono Cohort	Sep 2025	Aug 2026
NCT06921759	Atopic Hand and Foot Dermatitis	A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis (ADtouch)	3	221	Percentage of Participants Achieving a Hand and Foot Investigator Global Assessment (HF-IGA) Score of 0 or 1 with ≥2-point Improvement from Baseline	May 2026	Jul 2026

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Lepodisiran

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06292013	Atherosclerotic Cardiovascular Disease[1]	A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	3	17300	Time to First Occurrence of Any Component of the Major Adverse Cardiovascular Event (MACE)-4 Composite Endpoint	Mar 2029	Mar 2029
NCT07613294	Atherosclerosis / Cardiovascular Diseases / Lipoprotein(a)	A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk – ACCLAIM-CTA	3	252	Percent Change from Baseline in Noncalcified Plaque (NCP) Volume	Apr 2029	Dec 2029

[1] Reduction of major adverse cardiovascular events (MACE) in patients with Atherosclerotic Cardiovascular Disease (ASCVD) and those at-risk for ASCVD

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Mirikizumab

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03519945	Ulcerative Colitis	A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)	3	1153	Percentage of Participants in Clinical Remission	Mar 2026	Apr 2028
NCT04232553	Crohn's Disease	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)	3	996	Percentage of Participants Achieving Endoscopic Response	Nov 2024	Mar 2028
NCT05509777	Crohn's Disease	A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (AMAY)	3	90	Percentage of Participants with Clinical Response by Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12 and Endoscopic Response by Simple Endoscopic Score for CD (SES-CD) at Week 52	Dec 2027	Apr 2028
NCT06937099	Crohn's Disease / Obesity	Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight (COMMIT-CD)	3	290	Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction	May 2028	May 2028
NCT06937086	Ulcerative Colitis / Obesity	Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC)	3	350	Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction	Apr 2028	Apr 2028
NCT07483099	Crohn's Disease	A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease	2	60	Percentage of Participants with Crohn's Disease who Achieve Endoscopic Response	Jun 2027	Mar 2028
NCT07186101	Ulcerative Colitis	LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: (TOPAZ-UC)	2	252	Percentage of participants who simultaneously achieve clinical remission and at least 10% weight reduction	May 2027	Mar 2029
NCT06598943	Ulcerative Colitis	A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis	2	143	Percentage of Participants Achieving Clinical Remission	Dec 2027	Sep 2028

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Muvalaplin

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT07157774	Atherosclerotic Cardiovascular Disease[1]	Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) (MOVE-Lp(a))	3	10450	Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint	Mar 2031	Mar 2031

[1] Reduction of major adverse cardiovascular events (MACE) in patients with Atherosclerotic Cardiovascular Disease (ASCVD) and those at-risk for ASCVD

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Olomorasib

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06119581	Carcinoma, Non-Small-Cell Lung	A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)	3	1264	Dose Optimization and Safety Lead-In Part B: Number of Participants with a TEAE	Nov 2027	Jan 2031
NCT06890598[1]	Carcinoma, Non-Small-Cell Lung	Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02)	3	700	Part A: Disease-Free Survival (DFS) by Investigator Assessment	May 2029	Feb 2032

[1] Also lists AstraZeneca

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Orforglipron

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05869903	Obesity / Overweight	A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)	3	3127	Mean Percent Change from Baseline in Body Weight	Jul 2025	Oct 2027
NCT06649045	Obstructive Sleep Apnea / Obesity	A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA)	3	600	Change from Baseline in Apnea-Hypopnea Index (AHI)	Nov 2026	Jan 2027
NCT06672939	Obesity / Overweight	A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities	3	150	Percent Change from Baseline in Body Mass Index (BMI)	Dec 2027	Jan 2031
NCT06948422	Hypertension	A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension)	3	974	Change from baseline in systolic blood pressure	Sep 2027	Sep 2027
NCT07241390	Cardiovascular Disease / Chronic Kidney Disease	A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)	3	7140	Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events	Aug 2031	Aug 2031
NCT07153471	Osteoarthritis	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee (ATTAIN-OA PAIN)	3	800	Change from Baseline in WOMAC Pain Subscale Score	Apr 2028	May 2028
NCT07223593	Peripheral Artery Disease	Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease (ATTAIN-PAD)	3	1205	Percent Change from Baseline in Maximum Walking Distance	Jun 2028	Jun 2028
NCT07202884	Stress Urinary Incontinence / Obesity	A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight (RESTRAIN-SUI)	3	1000	Change from Baseline in Incontinence Episode Frequence (IEF)	Mar 2028	Mar 2028

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Orforglipron (cont.)

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06972459	Obesity / Overweight	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity	3	800	Percent Change from Baseline in Body Weight	Aug 2027	Aug 2027
NCT06972472	Obesity / Overweight	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes	3	600	Change from Baseline in Hemoglobin A1c (HbA1c)	Aug 2027	Aug 2027
NCT07668336	Diabetes Mellitus, Type 2	A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes	3	170	Change from Baseline in Hemoglobin A1c (HbA1c)	Mar 2030	Mar 2030
NCT07613307	Diabetes Mellitus, Type 2	A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting	3	130	Change from Baseline in Hemoglobin A1C (HbA1c)	May 2027	May 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Pirtobrutinib

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05023980	Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma	A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)	3	309	To evaluate progression-free survival (PFS) of pirtobrutinib (Arm A) compared to bendamustine and rituximab (Arm B)	Jul 2025	Oct 2027
NCT05254743	Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma	A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314)	3	737	Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (Cri), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 1	Oct 2027	Jan 2028
NCT04666038	Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma	Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)	3	238	Progression-Free Survival (PFS) Assessed by Independent Review Committee (IRC)	Aug 2023	May 2027
NCT04965493	Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma	A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)	3	600	To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B)	Oct 2026	Oct 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Pirtobrutinib (cont.)

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04662255	Mantle Cell Lymphoma	Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)	3	500	To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)	Jan 2027	Apr 2028
NCT06721013	Immune Thrombocytopenia	A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia	1/2	68	Ph. 1 - Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	May 2028	May 2029

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Remternetug

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06653153	Alzheimer's Disease	A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)	3	1400	Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR)	Apr 2029	Oct 2030

[1] CT.gov update in progress

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Retatrutide

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06662383	Obesity	A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)	3	800	Percent Change from Baseline in Body Weight	Nov 2026	Dec 2026
NCT06859268	Obesity	A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity (TRIUMPH-6)	3	643	Percent Change from Baseline in Body Weight	Apr 2028	Apr 2028
NCT07035093	Obesity / Chronic Low Back Pain	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7)	3	586	Percent Change from Baseline in Body Weight | Change from Baseline in Pain Intensity Per Numeric Rating Scale	Sep 2027	Sep 2027
NCT07232719	Obesity / Overweight	A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)	3	250	Percent Change from Baseline in Body Weight	Jul 2027	Jul 2027
NCT07357415	Obesity / Overweight	A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-9)	3	600	Percent Change from Baseline in Body Weight	Oct 2028	Nov 2028
NCT06383390	Atherosclerotic Cardiovascular Disease / CKD	The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	3	10000	Time to First Occurrence of Composite Endpoints	Feb 2029	Feb 2029
NCT06260722	Type 2 Diabetes	Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)	3	1250	Change from Baseline in HbA1c	Aug 2026	Jan 2027
NCT06297603	Type 2 Diabetes	Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)	3	320	Change from Baseline in HbA1c	Oct 2026	Nov 2026

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Selpercatinib

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04194944	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)	3	261	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)	May 2023	Jun 2030
NCT04819100	Non-Small Cell Lung Cancer	A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)	3	152	Event-Free Survival (EFS), EFS by Investigator Assessment in the Primary Analysis Population	Jan 2026	May 2028
NCT04211337	Medullary Thyroid Cancer	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	3	291	Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR)	May 2023	Nov 2027
NCT03157128	Non-Small Cell Lung Cancer / Medullary Thyroid Cancer	A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)	1/2	857	Phase 1: MTD, Incidence rate and category of dose limiting toxicities (DLTs) during the first 28-day cycle of LOXO-292 (selpercatinib) treatment	Feb 2025	Feb 2027
NCT03899792	Solid Tumors / CNS Tumors (Pediatric)	A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (LIBRETTO-121)	1/2	36	Number of Participants With Dose-Limiting Toxicities (DLTs)	Nov 2024	May 2029

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Sofetabart Mipitecan

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT07213804	Ovarian Neoplasms	A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer (FRAmework-01)	3	1630	Progression-free Survival (PFS), per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator	Nov 2028	Aug 2031

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Tirzepatide

Source: clinicaltrials.gov, July 30, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05556512	Obesity / Overweight	A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)	3	15374	Time to First Occurrence of a Major Adverse Cardiovascular Event (MACE) or All-Cause Death	Oct 2027	Oct 2027
NCT06914895	Type 1 Diabetes / Obesity	A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-1)	3	905	Change from Baseline in HbA1c	Nov 2026	Dec 2026
NCT06962280	Type 1 Diabetes / Obesity	A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-2)	3	465	Change from Baseline in HbA1c	Nov 2026	Jul 2027
NCT06439277	Obesity (Adolescents)	A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)	3	300	Percent Change from Baseline in Body Mass Index (BMI)	Oct 2027	Dec 2030
NCT06075667	Obesity / Overweight (Adolescents)	A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities	3	160	Percent Change from Baseline in Body Mass Index (BMI)	Jun 2026	Jul 2029
NCT07165028	MASLD	A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)	3	4500	Time to First Occurrence of Any Component of the Composite Endpoint for Major Adverse Liver Outcomes	Aug 2030	Aug 2032
NCT05536804	Obesity / Chronic Kidney Disease	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TREASURE-CKD)	2	140	Change from Baseline in Kidney Oxygenation in Participants With or Without T2D	Sep 2026	Oct 2026
NCT06037252	Type 2 Diabetes / Obesity	A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity	2	414	Percent Change From Baseline in Body Weight	Jan 2026	Oct 2026

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Early Phase Cardiometabolic Health

Source: clinicaltrials.gov, July 30, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Bimagrumab	NCT06643728	Obesity / Overweight	A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight	2	252	Percent Change from Baseline in Body Weight	Jan 2026	Jan 2027
GS Insulin Receptor Agonist	NCT07215312	Type 2 Diabetes	A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin	2	100	Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis)	Nov 2026	Dec 2026
Macupatide	NCT07215559	Obesity / Overweight / T2D	A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes	2	200	Percent Change from Baseline in Body Weight	Mar 2027	May 2027
Macupatide	NCT07589608	Overweight / Obesity	A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight	2	400	Percent Change from Baseline in Body Weight	Sep 2027	Feb 2028

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Early Phase Cardiometabolic Health, continued

Source: clinicaltrials.gov, July 30, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Nisotirostide	NCT06897475	Type 2 Diabetes	A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide	2	240	Change from Baseline in HbA1c	Dec 2026	Jan 2027
NLRP3 INH II	NCT06836232	Recurrent Pericarditis	An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis	2	50	Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to study treatment discontinuation (or Safety and tolerability of VTX2735)	Oct 2027	Oct 2027
Solbinsiran	NCT07269210	Severe Hypertriglyceridemia	A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia	2	60	Change from Baseline in Triglycerides	Mar 2027	Aug 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Early Phase Immunology

Source: clinicaltrials.gov, July 30, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Eltrekibart	NCT06046729	Hidradenitis Suppurativa	A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	2	352	Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)	Sep 2025	Aug 2026
Zotemtegrast	NCT07415044	Ulcerative Colitis	LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)	2	1431	Percentage of Participants Who Achieve Clinical Remission with Modified Mayo Score (mMS)	Jun 2030	Jul 2031
Zotemtegrast	NCT06226883	Crohn's Disease	A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease	2	385	Proportion of participants with endoscopic response at Week 14 determined using the Simple Endoscopic Score-CD (SES-CD)	Sep 2028	Jun 2030
Zotemtegrast	NCT05611671	Ulcerative Colitis	A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC (EMERALD-2)	2	280	Percentage of participants in clinical remission at Week 12 as determined using the Modified Mayo Clinic Score (mMCS)	Nov 2024	Aug 2026
XCL1/2 antibody	NCT07533019	Non-Segmental Vitiligo	A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo	2	66	Percentage of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI) 75	May 2027	Sep 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Early Phase Infectious Disease

Source: clinicaltrials.gov, July 30, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Amezosvatein	NCT05304351	Herpes Zoster	Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older	2	1516	Occurrence of solicited local and systemic signs and symptoms	Jun 2026	Mar 2032

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Early Phase Neuroscience

Source: clinicaltrials.gov, July 30, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Cleminorexton	NCT07598708	Central Disorders of Hypersomnolence	A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence	2/3	222	Change from baseline in mean sleep latency (average of the first 4 trials) on the Maintenance of Wakefulness Test (MWT)	Sep 2027	Dec 2027
AT2R Antagonist	NCT07285018	Diabetic Peripheral Neuropathic Pain	A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain	2	150	Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)	Jul 2027	Jul 2027
NAV 1.8 INH	NCT07511816	Pain Following Third Molar Removal	A Study of LY4515100 in Participants With Pain Following Third Molar Removal	2	212	Change from Baseline in Self-Reported Pain Intensity	Nov 2026	Dec 2026
Anti-VEGF Gene Therapy	NCT06517888	Vestibular Schwannoma	Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma	1/2	27	AEs with Relationship to the Investigational Medicinal Product and/or to the Administration Procedure (including the Delivery Device)	Aug 2029	Aug 2029
GBA1 Gene Therapy	NCT04127578	Parkinson's Disease (GBA1 Mutation)	Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)	1/2	32	Cumulative number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Dec 2030	Dec 2030
OTOF Gene Therapy	NCT05821959	Sensorineural Hearing Loss, Bilateral	Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss	1/2	22	Frequency of Adverse Events	Oct 2028	Oct 2028

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Early Phase Oncology

Source: clinicaltrials.gov, July 30, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
GIPR Agonist LA	NCT07169851	Chemotherapy-Induced Nausea / Vomiting	A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer	2	204	Proportion of Participants With Complete Response (CR) in the Delayed Phase of CINV	Dec 2026	Feb 2027
Tersolisib	NCT05768139	Breast Cancer	First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (PIKALO-1)	1/2	880	Number of participants who experience at least 1 Dose Limiting Toxicity (DLT)	Jul 2030	Jul 2030

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Trademarks

All trademarks and trade names referred to in this earnings update are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this earnings update, the property of their respective owners. Solely for convenience, the trademarks and trade names in this earnings update are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.